About

About iBody Inc. iBody has an unique monoclonal antibody generating technology called “Ecobody" that integrates single-cell technology and in vitro antibody expression technology. The "Ecobody" enables us to obtain monoclonal antibodies rapidly and efficiently from rabbits and humans, thereby producing antibodies with excellent properties necessary for therapeutics, diagnostics and reagents. About iBody Inc. iBody has an unique monoclonal antibody generating technology called “Ecobody" that integrates single-cell technology and in vitro antibody expression technology. The "Ecobody" enables us to obtain monoclonal antibodies rapidly and efficiently from rabbits and humans, thereby producing antibodies with excellent properties necessary for therapeutics, diagnostics and reagents. iBody has a patent protected monoclonal antibody discovery platform technology. It enabled us the exhaustive and world fastest (2 days) monoclonal antibody discovery. We have commercial success in monoclonal antibody discovery for pharmaceutical and diagnostic drug companies in Japan. These monoclonal antibodies have been applied to drug discovery, diagnostic drug development, and research tools. Platform technology: Extremely effective antibody discovery technology, which integrates single cell and cell free antibody technologies. Advantage: iBody technology enables discovering highly functional monoclonal antibodies that are difficult to obtain conventional technologies. Business model: - Contract research (Service) - Collaborative research iBody Inc. is a Japan-based biotechnology company with a proprietary antibody discovery platform that integrates single-cell technology with cell-free antibody expression. This unique combination enables extremely comprehensive and rapid antibody screening, allowing the discovery of antibodies that are difficult or impossible to generate using conventional methods. Our platform enables the discovery of high-performance antibodies from diverse sources, including rabbits, alpaca-derived VHH, and human samples. It is particularly powerful for challenging targets such as small molecules, post-translational modifications, single amino acid variants, and GPCRs. Building on this platform, we collaborate with pharmaceutical and diagnostic companies, and academics on antibody discovery programs. To date, we have advanced more than 100 programs with leading partners across pharma, diagnostics, and academia, consistently delivering high-value antibodies for difficult targets.